Cargando…

Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data

BACKGROUND: Liver biopsy is considered as the gold standard for assessing non-alcoholic fatty liver disease (NAFLD) histologic lesions in patients with severe obesity. The aim of this study was to perform an overview of 3 studies which assessed the performance of non-invasive markers of fibrosis (Fi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poynard, Thierry, Lassailly, Guillaume, Diaz, Emmanuel, Clement, Karine, Caïazzo, Robert, Tordjman, Joan, Munteanu, Mona, Perazzo, Hugo, Demol, Bernard, Callafe, Robert, Pattou, François, Charlotte, Frederic, Bedossa, Pierre, Mathurin, Philippe, Ratziu, Vlad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3303768/ https://www.ncbi.nlm.nih.gov/pubmed/22431959 http://dx.doi.org/10.1371/journal.pone.0030325

Ejemplares similares

Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus
por: Bril, Fernando, et al.
Publicado: (2019)

Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference
por: Munteanu, M., et al.
Publicado: (2016)

The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis
por: Poynard, Thierry, et al.
Publicado: (2019)

Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest)
por: Munteanu, Mona, et al.
Publicado: (2004)

The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis
por: Poynard, Thierry, et al.
Publicado: (2005)

An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load
por: Ngo, Yen, et al.
Publicado: (2008)

Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C
por: Poynard, Thierry, et al.
Publicado: (2004)

Correction: An Accurate Definition of the Status of Inactive Hepatitis B Virus Carrier by a Combination of Biomarkers (FibroTest-ActiTest) and Viral Load
por: Ngo, Yen, et al.
Publicado: (2008)

A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease
por: Halfon, Philippe, et al.
Publicado: (2002)

Noninvasive biomarkers FibroTest and ActiTest versus liver biopsy in chronic hepatitis C patients: the Middle East experience
por: Yakoob, Rafie, et al.
Publicado: (2015)

Non-invasive evaluation of the liver disease severity in children with chronic viral hepatitis using FibroTest and ActiTest – comparison with histopathological assessment
por: Pokorska-Śpiewak, Maria, et al.
Publicado: (2017)

Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease
por: Poynard, Thierry, et al.
Publicado: (2006)

Meta-analyses of FibroTest diagnostic value in chronic liver disease
por: Poynard, Thierry, et al.
Publicado: (2007)

Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age
por: Poynard, Thierry, et al.
Publicado: (2011)

Impact of steatosis and inflammation definitions on the performance of NASH tests
por: Poynard, Thierry, et al.
Publicado: (2018)

Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)
por: Poynard, Thierry, et al.
Publicado: (2010)

Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease
por: Ratziu, Vlad, et al.
Publicado: (2006)

Long‐term prognostic value of the FibroTest in patients with non‐alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease
por: Munteanu, Mona, et al.
Publicado: (2018)

UCx Prototype Target Tests for ActiLab-ENSAR
por: Andrighetto, A; INFN-LNL, et al.
Publicado: (2011)

Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis
por: Friedrich-Rust, Mireen, et al.
Publicado: (2010)

Prospective Validation of ELF Test in Comparison with Fibroscan and FibroTest to Predict Liver Fibrosis in Asian Subjects with Chronic Hepatitis B
por: Kim, Beom Kyung, et al.
Publicado: (2012)

UC$_{x}$ prototype target tests for ActiLab-ENSAR
por: Andrighetto, A, et al.
Publicado: (2012)

Discordance between Liver Biopsy and FibroTest in Assessing Liver Fibrosis in Chronic Hepatitis B
por: Park, Mi Sung, et al.
Publicado: (2013)

Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes
por: Poynard, Thierry, et al.
Publicado: (2019)

Prospective Validation of FibroTest in Comparison with Liver Stiffness for Predicting Liver Fibrosis in Asian Subjects with Chronic Hepatitis B
por: Kim, Beom Kyung, et al.
Publicado: (2012)

FibroTest for Evaluating Fibrosis in Non-Alcoholic Fatty Liver Disease Patients: A Systematic Review and Meta-Analysis
por: Vali, Yasaman, et al.
Publicado: (2021)

Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease
por: Nascimbeni, Fabio, et al.
Publicado: (2016)

Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis
por: Rudler, Marika, et al.
Publicado: (2015)

HEPATITIS VIRUS C INFECTION, ADIPOKINES AND HEPATIC STEATO–FIBROSIS
por: Ciurtin, C, et al.
Publicado: (2008)

Test, test, test!
por: Woodcock, J. A.
Publicado: (2020)

Laudator Temporis Acti
Publicado: (1905)

Letter to the editor: Regression of liver fibrosis after bariatric operations: A glass two‐third full rather than half empty
por: Pattou, François, et al.
Publicado: (2022)

COVID-19: Test, Test and Test
por: Saleh, Fatima A, et al.
Publicado: (2020)

Lifestyle interventions for patients with non-alcoholic steato-hepatitis–Design, rationale and protocol of the study “target group-specific optimisation of lifestyle interventions for behavior change in non-alcoholic steato-hepatitis (OPTI-NASH)”
por: Krüger, Kathrin, et al.
Publicado: (2023)

Memores Acti Prudentes Future!
por: Kulkarni, Atul P, et al.
Publicado: (2022)

A New SteatoScore in the Evaluation of Non-Alcoholic Liver Disease in Oncologic Patients
por: Cioni, Dania, et al.
Publicado: (2022)

Tests, testing, and tested - we need to critically evaluate the meaning of tests in psychiatry
por: Berger, Douglas M.
Publicado: (2013)

‘Test, re-test, re-test’: using inaccurate tests to greatly increase the accuracy of COVID-19 testing
por: Ramdas, Kamalini, et al.
Publicado: (2020)

Covid‐19 Control and the Economy: Test, Test, Test
por: Taamouti, Abderrahim
Publicado: (2021)

Test, test, test – a complication of testing for coronavirus disease 2019 with nasal swabs
por: Mughal, Z, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qtpnu58e5lg6po2387etq84c3v